Code intelligence

FDA-NDA204819 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-NDA204819.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated

Critical

High

100%

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: ADEMPAS (RIOCIGUAT) — Type 1 - New Molecular Entity

Policy FDA-NDA204819 · Pulmonology

High

Adempas (riociguat) is an oral tablet approved for pulmonary hypertension indications and follows a Part D billing pathway, consistent with its oral route of administration. As an orphan drug and new

View alert

Audit documentation

Building an audit file that includes FDA-NDA204819?

The Tripwire Audit Pack exports 12 months of Pulmonology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Pulmonology audit pack — $349One-time purchase · not a subscription